Percheron Therapeutics Ltd
ASX:PER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Advanced Enzyme Technologies Ltd
NSE:ADVENZYMES
|
IN |
|
hGears AG
XETRA:HGEA
|
DE |
|
Bayer AG
XETRA:BAYN
|
DE |
Percheron Therapeutics Ltd
Accrued Liabilities
Percheron Therapeutics Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Percheron Therapeutics Ltd
ASX:PER
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Accrued Liabilities
AU$3.9k
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Accrued Liabilities
AU$140.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Accrued Liabilities
AU$2.5m
|
CAGR 3-Years
52%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Accrued Liabilities
AU$244.4k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Percheron Therapeutics Ltd
Glance View
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
